NEWSROOM
News & Stories
Newsroom
Press Releases
MammaPrint Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment
Retrospective analysis of patient samples from the prospective, randomized Stockholm Tamoxifen Trial demonstrates clinical utility of MammaPrint in identifying breast cancer patients with exceedingly low likelihood for late recurrence at 20-years MammaPrint Late Recurrence (20yr) Read More
Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients
A multi-center trial demonstrated that MammaPrint identified 30% more low risk patients than the 21-gene test. MammaPrint Low Risk patients had an excellent 98.9% 5-year metastasis free survival Data from the I-SPY 2 trial reported Read More
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., IRVINE Calif., June 2, 2017-Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today Read More







